A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas Meeting Abstract


Authors: Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Abstract Title: A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas
Meeting Title: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 26
Issue: 15 Suppl.
Meeting Dates: 2008 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2008-05-20
Start Page: 457s
Language: English
ACCESSION: WOS:000208457403158
DOI: 10.1200/jco.2008.26.15_suppl.8512
PROVIDER: wos
Notes: Meeting Abstract: 8512 -- Source: Wos
Altmetric Score
MSK Authors
  1. Carol Portlock
    178 Portlock
  2. Craig Moskowitz
    368 Moskowitz
  3. Ariela Noy
    204 Noy
  4. Andrew D Zelenetz
    546 Zelenetz
  5. Paul Hamlin
    170 Hamlin
  6. David J Straus
    205 Straus